{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:34:06Z","timestamp":1794969246312,"version":"4.9.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1097\/md.0000000000005859","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T15:05:01Z","timestamp":1487171101000},"page":"e5859","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection"],"prefix":"10.1097","volume":"96","author":[{"given":"Jing","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210309","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"R2-9-20210309","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3748\/wjg.v20.i3.665","article-title":"Eradication of Helicobacter pylori infection: which regimen first?","volume":"20","author":"Federico","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R3-9-20210309","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"R4-9-20210309","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","article-title":"Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial","volume":"381","author":"Liou","year":"2013","journal-title":"Lancet"},{"key":"R5-9-20210309","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","article-title":"Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori","volume":"26","author":"Fischbach","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-9-20210309","first-page":"704","article-title":"Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy","volume":"99","author":"Huang","year":"2000","journal-title":"J Formos Med Assoc"},{"key":"R7-9-20210309","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection-the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"R8-9-20210309","first-page":"832","article-title":"pylori Study Group, Chinese Society of GastroenterologyThe third national consensus report on several issues of Helicobacter pylori infection.","volume":"51","year":"2012","journal-title":"Chin J Gastroenterol"},{"key":"R9-9-20210309","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1523-5378.2012.00962.x","article-title":"Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics","volume":"17","author":"Salazar","year":"2012","journal-title":"Helicobacter"},{"key":"R10-9-20210309","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1523-5378.2010.00758.x","article-title":"High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication","volume":"15","author":"Sun","year":"2010","journal-title":"Helicobacter"},{"key":"R11-9-20210309","doi-asserted-by":"crossref","first-page":"478","DOI":"10.5009\/gnl14020","article-title":"Efficacy of 7-day and 14-day bismuth-containing quadruple therapy and 7-day and 14-day moxifloxacin-based triple therapy as second-line eradication for helicobacter pylori infection","volume":"9","author":"Lee","year":"2014","journal-title":"Gut Liver"},{"key":"R12-9-20210309","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/gut.2009.198309","article-title":"Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design","volume":"59","author":"Liou","year":"2010","journal-title":"Gut"},{"key":"R13-9-20210309","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1572-0241.2006.00716.x","article-title":"Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication","volume":"101","author":"Nista","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R14-9-20210309","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2036.2007.03384.x","article-title":"First-line triple therapy with levofloxacin for Helicobacter pylori eradication","volume":"26","author":"Gisbert","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-9-20210309","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-9-20210309","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejim.2010.07.009","article-title":"Treatment of Helicobacter pylori infection: the past and the future","volume":"2","author":"Gisbert","year":"2010","journal-title":"Eur J Intern Med"},{"key":"R17-9-20210309","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"R18-9-20210309","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MCG.0b013e3181c8a1a3","article-title":"Sequential therapy for Helicobacter pylori eradication: a critical review","volume":"44","author":"Gisbert","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"R19-9-20210309","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2013-304820","article-title":"Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice","volume":"63","author":"McNicholl","year":"2014","journal-title":"Gut"},{"key":"R20-9-20210309","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/jcp.41.2.207","article-title":"Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies","volume":"41","author":"Goodwin","year":"1988","journal-title":"J Clin Pathol"},{"key":"R21-9-20210309","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1155\/2000\/709640","article-title":"Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens","volume":"14","author":"Chiba","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"R22-9-20210309","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"R23-9-20210309","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7753(00)71237-1","article-title":"Treatment for the eradication of Helicobacter pylori Recommendations of the Spanish Consensus Conference","volume":"114","author":"Gisbert","year":"2000","journal-title":"Med Clin"},{"key":"R24-9-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1746.1998.tb00537.x","article-title":"Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection","volume":"13","author":"Lam","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"R25-9-20210309","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/hel.12086","article-title":"The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study","volume":"18","author":"Erg\u00fcl","year":"2013","journal-title":"Helicobacter"},{"key":"R26-9-20210309","first-page":"CD008337","article-title":"Optimum duration of regimens for Helicobacter pylori eradication","volume":"12","author":"Yuan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-9-20210309","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1523-5378.2012.00993.x","article-title":"Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China","volume":"17","author":"Qian","year":"2012","journal-title":"Helicobacter"},{"key":"R28-9-20210309","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14656566.2013.763926","article-title":"Current options for the treatment of Helicobacter pylori","volume":"14","author":"Georgopoulos","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R29-9-20210309","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1572-0241.2006.00716.x","article-title":"Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication","volume":"101","author":"Nista","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R30-9-20210309","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.clinthera.2010.11.005","article-title":"Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults","volume":"32","author":"Pan","year":"2010","journal-title":"Clin Ther"},{"key":"R31-9-20210309","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejim.2010.05.011","article-title":"Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study","volume":"21","author":"Assem","year":"2010","journal-title":"Eur J Intern Med"},{"key":"R32-9-20210309","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"R33-9-20210309","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/hel.12046","article-title":"Antibiotic resistance of Helicobacter pylori Isolated in the southeast coastal region of China","volume":"11","author":"Su","year":"2013","journal-title":"Helicobacter"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:41:47Z","timestamp":1620960107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201702170-00009"}},"subtitle":["A 1-week, open-label, randomized trial"],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005859","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}